克隆性血液形成与心脏手术后的长期不良结果有关
Sandro Ninni1,2, Rocio Vicario3, Augustin Coisne1
1Université de Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID Lille France.
Journal of the American Heart Association
|August 29, 2024
概括
心脏手术后的克隆性血液形成 (CH) 是常见的,并使主要不良临床结果的长期风险增加一倍. 识别CH可能有助于个性化患者管理,并改善长期心脏手术的结果.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 心脏外科手术引起天生的免疫反应,可能导致术后并发症.
- 克隆性血液形成 (CH) 与心脏手术后的短期结果有关,但其长期影响尚不清楚.
研究的目的:
- 调查在接受心脏手术的患者中,克隆性血液形成与长期临床结果之间的关联.
主要方法:
- 一项队列研究包括2017年1月至2019年9月期间接受选择性心脏手术的患者.
- 患者使用19基因小组进行了CH选.
- 记录了临床事件,包括全因死亡和主要的心脏和大脑不良事件. 主要结局是所有原因死亡率和主要心脏和大脑不良事件的复合.
主要成果:
- 在314名患者中,139名 (44%) 患有CH. 冠状动脉疾病携带者有较高的先前心房的发病率.
- 最常见的突变是在DNMT3A,TET2和ASXL1基因中.
- 经过1203天的中位随访后,CH独立地与初级结局风险增加88%相关 (HR,1.88;P=0.035).
结论:
- 克隆性血液形成在心脏手术患者中很普遍,意味着主要不良临床结果的长期风险翻倍.
- 冠心病代表了心脏手术后长期并发症的新风险因素,可能有助于个性化管理策略.
更多相关视频
08:43Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
11.0K
08:14Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
Published on: October 3, 2019
12.2K
相关概念视频
Bone Marrow Sampling and Transplants
316
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
316
Tissue Transplantation
346
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
346
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
